CH681425A5 - - Google Patents
Download PDFInfo
- Publication number
- CH681425A5 CH681425A5 CH3616/90A CH361690A CH681425A5 CH 681425 A5 CH681425 A5 CH 681425A5 CH 3616/90 A CH3616/90 A CH 3616/90A CH 361690 A CH361690 A CH 361690A CH 681425 A5 CH681425 A5 CH 681425A5
- Authority
- CH
- Switzerland
- Prior art keywords
- trp
- cys
- phe
- thr
- microparticles
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 19
- 239000011859 microparticle Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 238000001125 extrusion Methods 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 9
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims description 9
- 229920002988 biodegradable polymer Polymers 0.000 claims description 8
- 239000004621 biodegradable polymer Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 102000005157 Somatostatin Human genes 0.000 claims description 4
- 108010056088 Somatostatin Proteins 0.000 claims description 4
- 229920002253 Tannate Polymers 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 4
- 229960000553 somatostatin Drugs 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 241000234435 Lilium Species 0.000 claims description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 3
- 239000012907 medicinal substance Substances 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 102000055006 Calcitonin Human genes 0.000 claims description 2
- 108060001064 Calcitonin Proteins 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
- 229960004015 calcitonin Drugs 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 claims 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 2
- ZMKVBUOZONDYBW-UHFFFAOYSA-N 1,6-dioxecane-2,5-dione Chemical compound O=C1CCC(=O)OCCCCO1 ZMKVBUOZONDYBW-UHFFFAOYSA-N 0.000 claims 1
- 229940102213 injectable suspension Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 description 9
- 230000006835 compression Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108700012941 GNRH1 Proteins 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 101710142969 Somatoliberin Proteins 0.000 description 2
- 229920000229 biodegradable polyester Polymers 0.000 description 2
- 239000004622 biodegradable polyester Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000012438 extruded product Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH3616/90A CH681425A5 (da) | 1990-11-14 | 1990-11-14 | |
BE9101009A BE1004923A5 (fr) | 1990-11-14 | 1991-10-31 | Procede de preparation d'une composition pharmaceutique. |
GB9123241A GB2249725B (en) | 1990-11-14 | 1991-11-01 | Biodegradable microparticles or implant containing insoluble peptide salts |
FR9113563A FR2668707B1 (fr) | 1990-11-14 | 1991-11-04 | Procede de preparation d'une composition pharmaceutique. |
CA002055115A CA2055115A1 (en) | 1990-11-14 | 1991-11-07 | A process for preparing a pharmaceutical composition |
ITBS910119A IT1252870B (it) | 1990-11-14 | 1991-11-08 | Procedimento di preparazione di una composizione farmaceutica sotto forma di microparticelle |
DE4136930A DE4136930A1 (de) | 1990-11-14 | 1991-11-11 | Verfahren zur herstellung einer pharmazeutischen zusammensetzung, die pharmazeutische zusammensetzung sowie deren verwendung |
NL9101877A NL9101877A (nl) | 1990-11-14 | 1991-11-11 | Werkwijze voor het bereiden van een farmaceutisch preparaat. |
AT0223591A AT397198B (de) | 1990-11-14 | 1991-11-12 | Verfahren zur herstellung einer zur kontinuierlichen und kontrollierten abgabe eines natürlichen oder synthetischen peptids bestimmten pharmazeutischen zusammensetzung, insbesondere in form von mikrokapseln bzw. implantaten |
US07/790,033 US5439688A (en) | 1989-07-28 | 1991-11-12 | Process for preparing a pharmaceutical composition |
ES09102518A ES2049617B1 (es) | 1990-11-14 | 1991-11-13 | Procedimiento de preparacion de una composicion farmaceutica. |
SE9103348A SE506448C2 (sv) | 1990-11-14 | 1991-11-13 | Förfarande för framställning av en farmaceutisk komposition innehållande en peptid |
JP91297358A JPH04288021A (ja) | 1990-11-14 | 1991-11-13 | 薬用組成物の製造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH3616/90A CH681425A5 (da) | 1990-11-14 | 1990-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CH681425A5 true CH681425A5 (da) | 1993-03-31 |
Family
ID=4259807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH3616/90A CH681425A5 (da) | 1989-07-28 | 1990-11-14 |
Country Status (12)
Country | Link |
---|---|
JP (1) | JPH04288021A (da) |
AT (1) | AT397198B (da) |
BE (1) | BE1004923A5 (da) |
CA (1) | CA2055115A1 (da) |
CH (1) | CH681425A5 (da) |
DE (1) | DE4136930A1 (da) |
ES (1) | ES2049617B1 (da) |
FR (1) | FR2668707B1 (da) |
GB (1) | GB2249725B (da) |
IT (1) | IT1252870B (da) |
NL (1) | NL9101877A (da) |
SE (1) | SE506448C2 (da) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
US5456917A (en) * | 1993-04-12 | 1995-10-10 | Cambridge Scientific, Inc. | Method for making a bioerodible material for the sustained release of a medicament and the material made from the method |
US5945128A (en) * | 1996-09-04 | 1999-08-31 | Romano Deghenghi | Process to manufacture implants containing bioactive peptides |
WO2004096178A1 (en) * | 2003-05-02 | 2004-11-11 | The University Of Nottingham | Nano and microparticle drug delivery systems comprising polyesters containing aliphatic dicarboxylate residues and residues of aliphatic polyols |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3978203A (en) * | 1974-07-12 | 1976-08-31 | Dynatech Corporation | Sustained release of pharmaceuticals from polyester matrices |
US4481353A (en) * | 1983-10-07 | 1984-11-06 | The Children's Medical Center Corporation | Bioresorbable polyesters and polyester composites |
US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
CH672887A5 (da) * | 1987-10-14 | 1990-01-15 | Debiopharm Sa | |
CH679207A5 (da) * | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
IT1243390B (it) * | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
-
1990
- 1990-11-14 CH CH3616/90A patent/CH681425A5/fr not_active IP Right Cessation
-
1991
- 1991-10-31 BE BE9101009A patent/BE1004923A5/fr not_active IP Right Cessation
- 1991-11-01 GB GB9123241A patent/GB2249725B/en not_active Expired - Fee Related
- 1991-11-04 FR FR9113563A patent/FR2668707B1/fr not_active Expired - Fee Related
- 1991-11-07 CA CA002055115A patent/CA2055115A1/en not_active Abandoned
- 1991-11-08 IT ITBS910119A patent/IT1252870B/it active IP Right Grant
- 1991-11-11 NL NL9101877A patent/NL9101877A/nl active Search and Examination
- 1991-11-11 DE DE4136930A patent/DE4136930A1/de not_active Ceased
- 1991-11-12 AT AT0223591A patent/AT397198B/de not_active IP Right Cessation
- 1991-11-13 SE SE9103348A patent/SE506448C2/sv not_active IP Right Cessation
- 1991-11-13 ES ES09102518A patent/ES2049617B1/es not_active Expired - Lifetime
- 1991-11-13 JP JP91297358A patent/JPH04288021A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2055115A1 (en) | 1992-05-15 |
NL9101877A (nl) | 1992-06-01 |
GB2249725A (en) | 1992-05-20 |
SE9103348L (sv) | 1992-05-15 |
FR2668707B1 (fr) | 1995-05-24 |
IT1252870B (it) | 1995-06-28 |
ITBS910119A0 (it) | 1991-11-08 |
ES2049617B1 (es) | 1997-03-16 |
ATA223591A (de) | 1993-07-15 |
FR2668707A1 (fr) | 1992-05-07 |
JPH04288021A (ja) | 1992-10-13 |
GB2249725B (en) | 1994-08-10 |
DE4136930A1 (de) | 1992-08-20 |
BE1004923A5 (fr) | 1993-02-23 |
AT397198B (de) | 1994-02-25 |
ITBS910119A1 (it) | 1993-05-08 |
GB9123241D0 (en) | 1991-12-18 |
SE506448C2 (sv) | 1997-12-15 |
ES2049617A1 (es) | 1994-04-16 |
SE9103348D0 (sv) | 1991-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CH679207A5 (da) | ||
US5439688A (en) | Process for preparing a pharmaceutical composition | |
US5225205A (en) | Pharmaceutical composition in the form of microparticles | |
RU2131244C1 (ru) | Твердая дозированная форма | |
DE69032976T2 (de) | Zubereitung von pharmazeutischen und anderen matrixsystemen durch auflösung in festem zustand | |
IE49584B1 (en) | Pancreatin pellets and process for the preparation thereof | |
FR2665360A1 (fr) | Procede de preparation de compositions a liberation prolongee et compositions ainsi obtenues. | |
HU203662B (en) | Process for producing microspheric compositions containing growth hormone and parenteral growth hormone compositions for enhancing productivity in milk and weight of animals and for raising level of growth hormone in the blood | |
EP0621777A1 (de) | Wirkstoff-enthaltende festkörper mit einem gerüst aus hydrophilen makromolekülen und verfahren zu ihrer herstellung. | |
CH681425A5 (da) | ||
KR20060109479A (ko) | 제약상 다입자의 제조 방법 | |
EP0440702B1 (en) | A pharmaceutical composition for rapid release of the active component comprising a solid dispersion and a surfactant | |
HUE033660T2 (en) | Spray containing fine particulate active ingredient | |
FR2515035A1 (fr) | Nouvelle forme galenique solide pour administration par voie orale et son procede de fabrication | |
FR2748205A1 (fr) | Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles | |
CH685285A5 (fr) | Procédé de préparation d'une composition pharmaceutique contenant des sels de peptides. | |
DE69422806T2 (de) | Herstellung von matrizes | |
JPH0278613A (ja) | 精油含有軟カプセル | |
CA2247877A1 (en) | Solubilizing delivery systems and method of manufacture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased |